MTOR and nonpapillary renal cell carcinoma: To evaluate the therapeutic effectiveness of targeting mTOR activity on the metastatic ccRCC with LTF downregulation, we next cultivated A498 cells with LTF knockdown in the absence or presence of mTOR inhibitor rapamycin (RAPA).